[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368894-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368894-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","beyond-borders-engineering-organ-targeted-immunotherapies-to-overcome-site-specific-barriers-in-cancer","Beyond borders - engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer","","Organ-targeted immunotherapy is emerging as a strategy to improve the precision, efficacy, and safety of cancer immunotherapy. Tumors originate in or metastasize to immunologically distinct organs—brain, liver, and lungs—each with barriers that reduce uniform treatment success through specialized immune microenvironments. Nanovaccine-based therapies are highlighted as a way to address organ-specific challenges, including the blood–brain barrier restricting penetration, the liver’s immune-tolerant and phagocyte-rich landscape suppressing antitumor activity in hepatocellular carcinoma, and the lungs’ exposure context requiring precise delivery. Engineered nanocarriers use passive targeting via EPR, active targeting with organ ligands, immune cell hitchhiking, and stimuli-responsive release to enable localized immune activation, tumor microenvironment remodeling, and stronger cytotoxic T-cell responses, supporting translation toward clinically viable therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/beyond-borders-engineering-organ-targeted-immunotherapies-to-overcome-site-specific-barriers-in-cancer/368894/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/beyond-borders-engineering-organ-targeted-immunotherapies-to-overcome-site-specific-barriers-in-cancer/368894.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are organ-specific barriers important in cancer immunotherapy?","Question",{"text":63,"@type":64},"Different organs create distinct immune microenvironments and physical barriers, which can prevent consistent treatment success. Understanding these barriers is necessary to design effective organ-specific immunotherapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do nanovaccine-based immunotherapies help overcome organ challenges?",{"text":68,"@type":64},"Engineered nanocarriers enable targeted delivery and localized immune activation. They can reshape the tumor microenvironment and enhance cytotoxic T-cell responses using strategies such as EPR targeting, organ ligands, hitchhiking, and stimuli-responsive release.",{"name":70,"@type":61,"acceptedAnswer":71},"What makes the brain particularly difficult for drug delivery and immunotherapy?",{"text":72,"@type":64},"The blood–brain barrier tightly regulates endothelial passage, limiting the entry of most therapeutic agents and immune cells. This creates a major obstacle for effective delivery, especially in aggressive cancers like glioblastoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368894,1790219573,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":97,"preview_urls":147},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Drug Delivery and Translational Research (2025) 15:4217–4259  \n[https://doi.org/10.1007/s13346-025-01935-4](https://doi.org/10.1007/s13346-025-01935-4)  \nBeyond borders: engineering organ‑targeted immunotherapies to overcome site‑specific barriers in cancer  \nThrinayan Moorthy1 · Bhanu NiroshaYalamandala1 · Thi My Hue Huynh1 · Hui‑Wen Lien1 · Wan‑Chi Pan1 · Hoi Man Iao1 · Yun‑Hsuan Chang1 · Shang‑Hsiu Hu1  \nAccepted: 24 July 2025 / Published online: 11 August 2025 © The Author(s) 2025  \nAbstract  \nOrgan-targeted immunotherapy is emerging as a transformative strategy to significantly improve the precision, efficacy, and safety of cancer immunotherapy. Tumors frequently arise in, or metastasize to, immunologically unique organs such as the brain, liver, and lungs—each presenting formidable barriers that impede uniform treatment success. These organs not only represent common metastatic sites but also host distinct immune microenvironments that demand customized therapeutic approaches. Nanovaccine-based immunotherapies have recently gained traction as a promising solution to overcome these organ-specific challenges. The brain, protected by the blood–brain barrier (BBB), limits immune cell infiltration and drug penetration, especially in aggressive cancers like glioblastoma (GBM) . The liver, characterized by its immune-tolerant landscape and dense population of phagocytic cells, suppresses antitumor responses in hepatocellular carcinoma (HCC) . Meanwhile, the lungs’ vast vasculature and continuous exposure to airborne antigens necessitate precision delivery strategies to trigger robust immunity without provoking excessive inflammation. To surmount these hurdles, nanocarriers have been engineered to leverage passive targeting through the enhanced permeability and retention (EPR) effect, active targeting via organ-specific ligands, immune cell hitchhiking, and stimuli-responsive release mechanisms. These innovations enable nanovaccines to elicit localized immune activation, reshape the tumor microenvironment (TME), and enhance cytotoxic T-cell responses. This review underscores the critical importance and urgent need for continued development of organ-specific nanovaccine platforms. It calls for intensified research efforts to translate these technologies into clinically viable therapies capable of addressing the most immunologically challenging tumor sites.  \nKeywords Lung cancer · Glioblastoma (GBM) · Hepatocellular carcinoma (HCC) · Nanovaccine · Immunotherapy · Cancer therapy  \nIntroduction  \nThe quest to eradicate cancer has persisted for over a century with limited treatment success, prompting researchers to explore interventions offering a permanent cure. While conventional approaches involving surgical resection, chemotherapy, and radiotherapy remain standard-of-care and can offer significant benefits, especially when tumors are detected at early stages, their effectiveness is often limited in advanced or metastatic cancers due to therapy resistance  \n* Shang-Hsiu Hu[shhu@mx.nthu.edu.tw](shhu@mx.nthu.edu.tw)  \n1 Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300044, Taiwan  \nand tumor immune evasion. This limited progress stems from malignant tumors adapting to evade therapy, involving metabolic rewiring that promotes unchecked proliferation and survival [1–3] . Moreover, the TME comprises complex immune cell networks, which tumors manipulate to avoid immune attack [4] . In response, researchers aim to harness the innate capabilities of immune cells to eliminate cancer. As a result, cancer immunotherapy has gained significant prominence by harnessing the immune system's power to combat tumors [5] .  \nTo address the limitations of systemic treatments, organ-targeted immunotherapy has emerged as a promising approach [6] . Given that each organ possesses unique structural and immunological features, generalized therapies often fall short [7]. Each organ presents unique p","cbCaidRHGPSBxciZ","https://ap.wps.com/l/cbCaidRHGPSBxciZ","pdf",3273930,43,"English","# Abstract\n# Keywords\n# Introduction\n## Background on cancer treatment limits\n## Rationale for organ-targeted immunotherapy\n## Organ-specific barriers: brain, lung, liver\n## Strategies for precision delivery and immunotherapy approaches","[{\"question\":\"Why are organ-specific barriers important in cancer immunotherapy?\",\"answer\":\"Different organs create distinct immune microenvironments and physical barriers, which can prevent consistent treatment success. Understanding these barriers is necessary to design effective organ-specific immunotherapies.\"},{\"question\":\"How do nanovaccine-based immunotherapies help overcome organ challenges?\",\"answer\":\"Engineered nanocarriers enable targeted delivery and localized immune activation. They can reshape the tumor microenvironment and enhance cytotoxic T-cell responses using strategies such as EPR targeting, organ ligands, hitchhiking, and stimuli-responsive release.\"},{\"question\":\"What makes the brain particularly difficult for drug delivery and immunotherapy?\",\"answer\":\"The blood–brain barrier tightly regulates endothelial passage, limiting the entry of most therapeutic agents and immune cells. This creates a major obstacle for effective delivery, especially in aggressive cancers like glioblastoma.\"}]","Beyond borders - engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer | PDF",1790179118,108,[148,152,156,160,164],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8425c0f7ce016953546d3edf5872541a.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4687b4ca2946ac4350e8b65073c6f095.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/743abea341161d54cd69c094b40ca863.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91271710a38cf8180863dd9d7bdbdf28.webp",980,1301,{"page_no":97,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/563c09ffc39766170b1b9f545877b6a5.webp",979,1300]